Major bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents probably leads to higher major bleeding compared with control (moderate certainty).
1 finding from 1 review
Major bleeding (minor cerebral hemorrhage) · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes major bleeding (minor cerebral hemorrhage) compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Any bleeding that does not meet criteria for major bleeding ‐ Gastrointestinal bleeding (no definition) · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes any bleeding that does not meet criteria for major bleeding ‐… compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Major bleeding · people requiring treatment for acute DVT
1 finding from 1 review
Major bleeding · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in major bleeding compared with BMP plus placebo (moderate certainty).
1 finding from 1 review
Major bleeding · people requiring treatment for chronic DVT
1 finding from 1 review
Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Major bleeding · asymptomatic carotid stenosis
It is very uncertain whether antiplatelet agent changes major bleeding (not reported) compared with placebo (very low certainty).
1 finding from 1 review
Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Major bleedinga · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin leads to higher major bleedinga compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) showed no clear difference in major bleeding compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Major bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Bleeding ‐ major/excessive · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Intervention not reported
Major bleeding events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention probably leads to higher major bleeding events at longest (moderate certainty).
1 finding from 1 review
Intervention not reported
Major bleeding events up to longest · non‐hospitalised adults with mild COVID‐19
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) showed no clear difference in clinically relevant non‐major bleeding compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
Bleeding ‐ major (bleeding requiring transfusion) Length of · people with antiphospholipid antibodies and no history of thrombosis
ASA with LMWH showed no clear difference in bleeding ‐ major (bleeding requiring transfusion) Length of compared with placebo or IVIG (moderate certainty).
1 finding from 1 review